Jones Hill Capital LP is an SEC-registered investment adviser based in New York, NY that reports managing 1 hedge fund on Form ADV. It reports $642.4 million in regulatory assets under management. Its private funds, of all types, hold $230.3 million in gross assets. Over a longer period they returned an estimated +15.0% from Q2 2026 to Q2 2026, compared with +14.8% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $642.4 millionForm ADV Item 5.F
- Gross assets of private funds
- $230.3 millionAll private fund types, Form ADV
- Hedge funds managed
- 11 private funds in total
- Employees
- 8Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 339686
- Latest Form ADV
- 05/06/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +15.0% | +14.8% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.
13F holdings as of Sep 30, 2026
All 33 share positions ($589,169,587) reported by Jones Hill Capital LP on Form 13F for the quarter ended Sep 30, 2026, filed Nov 13, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.
Share of the reported 13F portfolio, ten largest positions
- Biomarin Pharmaceutical Inc11.93%
- Biocryst Pharmaceuticals Inc10.01%
- Travere Therapeutics Inc9.59%
- Indivior Pharmaceuticals Inc9.29%
- Pharvaris N V5.32%
- Celcuity Inc5.17%
- Ionis Pharmaceuticals Inc4.55%
- Supernus Pharmaceuticals4.40%
- Nuvation Bio Inc4.26%
- Vera Therapeutics Inc3.57%
| Stock | Value | % of 13F portfolio | Shares | Shares vs prior quarter |
|---|---|---|---|---|
| Biomarin Pharmaceutical Inc | $70,311,540 | 11.93% | 1,171,859 | -18.14% |
| Biocryst Pharmaceuticals Inc | $59,003,889 | 10.01% | 7,083,300 | New |
| Travere Therapeutics Inc | $56,503,250 | 9.59% | 959,634 | New |
| Indivior Pharmaceuticals Inc | $54,731,657 | 9.29% | 1,526,685 | New |
| Pharvaris N V | $31,327,846 | 5.32% | 987,637 | +45.70% |
| Celcuity Inc | $30,448,288 | 5.17% | 382,901 | New |
| Ionis Pharmaceuticals Inc | $26,782,231 | 4.55% | 599,826 | New |
| Supernus Pharmaceuticals | $25,896,522 | 4.40% | 601,685 | New |
| Nuvation Bio Inc | $25,127,122 | 4.26% | 4,486,986 | New |
| Vera Therapeutics Inc | $21,060,119 | 3.57% | 652,218 | New |
| Trevi Therapeutics Inc | $20,723,274 | 3.52% | 1,447,156 | +8.06% |
| Bicara Therapeutics Inc | $19,805,376 | 3.36% | 1,064,233 | +19.23% |
| Relmada Therapeutics Inc | $19,745,858 | 3.35% | 5,237,628 | -4.47% |
| Abivax SA | $14,116,093 | 2.40% | 142,558 | New |
| Aclaris Therapeutics Inc | $13,174,464 | 2.24% | 2,504,651 | +42.35% |
| Insmed Inc | $12,159,106 | 2.06% | 106,528 | -12.95% |
| Neurocrine Biosciences Inc | $11,833,144 | 2.01% | 83,426 | New |
| Immunocore Hldgs PLC | $11,639,781 | 1.98% | 384,278 | -25.07% |
| Erasca Inc | $8,944,330 | 1.52% | 610,118 | New |
| Capricor Therapeutics Inc | $8,452,278 | 1.43% | 892,532 | +6.06% |
| Dianthus Therapeutics Inc | $7,045,497 | 1.20% | 80,017 | +40.13% |
| Neurogene Inc | $6,056,414 | 1.03% | 217,700 | New |
| Corbus Pharmaceuticals Hldgs | $6,045,439 | 1.03% | 886,428 | +35.63% |
| Tonix Pharmaceuticals Hldg C | $5,490,818 | 0.93% | 563,739 | -9.86% |
| Sagimet Biosciences Inc | $4,965,560 | 0.84% | 502,587 | New |
| Dyne Therapeutics Inc | $4,847,499 | 0.82% | 300,900 | New |
| Avalyn Pharmaceuticals Inc | $3,610,937 | 0.61% | 126,744 | New |
| Attovia Therapeutics Inc | $3,124,536 | 0.53% | 182,295 | New |
| Phathom Pharmaceuticals Inc | $2,020,859 | 0.34% | 276,830 | +71.43% |
| Lexeo Therapeutics Inc | $2,006,831 | 0.34% | 593,737 | New |
| Olema Pharmaceuticals Inc | $1,783,270 | 0.30% | 206,397 | -64.05% |
| Tenax Therapeutics Inc | $230,899 | 0.04% | 122,169 | New |
| Alvotech | $154,860 | 0.03% | 26,700 | New |
Changes since Jun 30, 2026
Comparing the share counts in the two quarter-end filings: 19 new positions, 15 sold out, 8 increased, 6 reduced and 0 unchanged.
Number of positions (a count, not dollars)
- New positions19
- Increased8
- Unchanged0
- Reduced6
- Sold out15
New positions
| Stock | Value | Shares |
|---|---|---|
| Biocryst Pharmaceuticals Inc | $59,003,889 | 7,083,300 |
| Travere Therapeutics Inc | $56,503,250 | 959,634 |
| Indivior Pharmaceuticals Inc | $54,731,657 | 1,526,685 |
| Celcuity Inc | $30,448,288 | 382,901 |
| Ionis Pharmaceuticals Inc | $26,782,231 | 599,826 |
| Supernus Pharmaceuticals | $25,896,522 | 601,685 |
| Nuvation Bio Inc | $25,127,122 | 4,486,986 |
| Vera Therapeutics Inc | $21,060,119 | 652,218 |
| Abivax SA | $14,116,093 | 142,558 |
| Neurocrine Biosciences Inc | $11,833,144 | 83,426 |
| Erasca Inc | $8,944,330 | 610,118 |
| Neurogene Inc | $6,056,414 | 217,700 |
| Sagimet Biosciences Inc | $4,965,560 | 502,587 |
| Dyne Therapeutics Inc | $4,847,499 | 300,900 |
| Avalyn Pharmaceuticals Inc | $3,610,937 | 126,744 |
| Attovia Therapeutics Inc | $3,124,536 | 182,295 |
| Lexeo Therapeutics Inc | $2,006,831 | 593,737 |
| Tenax Therapeutics Inc | $230,899 | 122,169 |
| Alvotech | $154,860 | 26,700 |
Sold out
| Stock | Value at Jun 30, 2026 | Shares held then |
|---|---|---|
| Gilead Sciences Inc | $43,340,053 | 343,043 |
| Arcutis Biotherapeutics Inc | $28,571,960 | 1,089,701 |
| Madrigal Pharmaceuticals Inc | $28,214,038 | 52,545 |
| Xenon Pharmaceuticals Inc | $22,206,444 | 367,900 |
| Ani Pharmaceuticals Inc | $19,354,626 | 233,808 |
| Amylyx Pharmaceuticals Inc | $16,057,282 | 894,058 |
| Nuvalent Inc | $12,157,587 | 98,442 |
| Immunic Inc | $8,296,941 | 539,814 |
| Oric Pharmaceuticals Inc | $8,093,400 | 747,313 |
| Syndax Pharmaceuticals Inc | $7,432,400 | 340,000 |
| Vir Biotechnology Inc | $6,717,380 | 659,213 |
| Vertex Pharmaceuticals Inc | $5,525,128 | 11,123 |
| Enliven Therapeutics Inc | $2,529,888 | 49,850 |
| Structure Therapeutics Inc | $2,177,231 | 40,567 |
| Achieve Life Science Inc | $174,743 | 26,760 |
Largest increases
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Pharvaris N V | +309,758 | +45.70% | $31,327,846 | 987,637 |
| Aclaris Therapeutics Inc | +745,159 | +42.35% | $13,174,464 | 2,504,651 |
| Bicara Therapeutics Inc | +171,612 | +19.23% | $19,805,376 | 1,064,233 |
| Dianthus Therapeutics Inc | +22,917 | +40.13% | $7,045,497 | 80,017 |
| Corbus Pharmaceuticals Hldgs | +232,856 | +35.63% | $6,045,439 | 886,428 |
| Trevi Therapeutics Inc | +107,944 | +8.06% | $20,723,274 | 1,447,156 |
| Phathom Pharmaceuticals Inc | +115,344 | +71.43% | $2,020,859 | 276,830 |
| Capricor Therapeutics Inc | +51,030 | +6.06% | $8,452,278 | 892,532 |
Largest reductions
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Biomarin Pharmaceutical Inc | -259,731 | -18.14% | $70,311,540 | 1,171,859 |
| Immunocore Hldgs PLC | -128,578 | -25.07% | $11,639,781 | 384,278 |
| Olema Pharmaceuticals Inc | -367,769 | -64.05% | $1,783,270 | 206,397 |
| Insmed Inc | -15,847 | -12.95% | $12,159,106 | 106,528 |
| Relmada Therapeutics Inc | -244,984 | -4.47% | $19,745,858 | 5,237,628 |
| Tonix Pharmaceuticals Hldg C | -61,689 | -9.86% | $5,490,818 | 563,739 |
Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.
From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures
Hedge funds filing Form D (2)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures